Skip to main content

Advertisement

Table 1 Anatomical and clinical CT-perfusion and 18 F-FDG-PET/CT characteristics of the histologic lung cancer subtypes

From: Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT

Tumor parameters All tumors (n = 46) Tumor type NSCLC subtypeb
SCLC (n = 5) NSCLC (n = 41) p Adenocarcinoma (n = 24) Squamous cell carcinoma (n = 9) Large cell carcinoma (n = 7) p
Anatomical characteristics         
 Longest diameter (mm), mean ± SD 41.1 ± 20.1 35.2 ± 18.5 42.0 ± 20.9 0.70 39.9 ± 20.9 45.8 ± 21.3 37.0 ± 9.9 0.80
 Location superior/inferior 83%/17% 80%/20% 83%/17% 0.92 87%/13% 100%/0% 43%/57% 0.008
 Location central/peripheral 43%/57% 80%/20% 39%/61% 0.14 33%/66% 66%/33% 29%/73% 0.18
Clinical characteristics         
 T stage (median (range)) T2a (T1 to T4b) T2a (T1b to T4) T2a (T1a to T4) 0.84 T2a (T1a to T4) T3 (T2a to T4) T2a (T1b to T2b) 0.008
  T1 5 1 4   2 0 2  
  T2 29 2 27 18 4 5
  T3 6 1 5 3 2 0
  T4 6 1 5 1 3 0
 N stage (median (range)) N1 (N0 to N3) N2 (N0 to N3) N1 (N0 to N3) 0.47 N2 (N0 to N3) N1 (N0 to N3) N0 (N0 to N3) 0.41
  N0 15 1 13   7 1 4  
  N1 10 0 11 4 6 1
  N2 9 3 6 5 0 1
  N3 12 1 11 8 2 1
 M stage (median (range)) M0 (M0 to M1) M0 (M0) M0 (M0 to M1)   M0 (M0 to M1) M0 (M0 to M1) M1 (M0 to M1) 0.89
  M0 28 5 23 0.41 14 6 3  
  M1 18 0 18 10 3 4
 UICC stage (median (range)) IIIB (IA to IV) IIIA (IIB to IIIB) IIIB (IA to IV) 0.32 IIIB (IA to IV) IIIA (IIA to IV) IV (IB to IV) 0.88
CT-perfusion characteristics         
 Blood flow (mL/100 mL min-1), mean ± SD 35.5 ± 23.5 35.5 ± 12.6 35.5 ± 24.3 0.67 31.4 ± 14.1 30.5 ± 9.8 56.9 ± 45.7 0.21
 Blood volume (mL/100 mL), mean ± SD 8.4 ± 6.4 8.6 ± 4.8 8.4 ± 6.4 0.85 9.1 ± 7.4 5.3 ± 2.8 9.9 ± 5.4 0.16
 Mean transit time (s), mean ± SD 14.2 ± 4.5 12.4 ± 3.8 14.4 ± 4.5 0.45 14.6 ± 4.4 16.3 ± 4.1 11.8 ± 4.0 0.30
18F-FDG-PET/CT characteristics         
 SUVmax (mean ± SD) 11.7 ± 5.5 9.1 ± 3.0 12.0 ± 5.6 0.35 11.3 ± 4.9 14.3 ± 5.8 9.7 ± 4.8 0.28
 SUVmean (42%) (mean ± SD) 7.2 ± 3.3 5.8 ± 1.7 7.4 ± 3.5 0.43 6.9 ± 2.9 8.9 ± 3.8 6.1 ± 3.0 0.29
 TLG (median (range)) 120.0 (1.9 to 2621) 87.8 (7.8 to 232) 124.3 (1.9 to 2621) 0.39 116.2 (1.9 to 1,900) 124.3 (30.5 to 1,555) 101.5 (33.2 to 243.5) 0.88
 PETvol (cm3) (median (range)) 17.0 (1.2 to 315) 12.6 (3.1 to 39.6) 18.2 (1.2 to 315) 0.58 18.1 (1.2 to 315) 14.1 (3.4 to 68.0) 18.2 (4.3 to 67.7) 0.93
 PET-positive lymph nodes 63% 100% 59% 0.14 64% 67% 43% 0.59
Microvessel densitya (1/mm2), mean ± SD 149.9 ± 79.7 - 149.9 ± 79.7 - 155.8 ± 75.9 153.7 ± 96.4 77.1 0.50
  1. 18F-FDG-PET/CT, 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography; CT, computed tomography; NSCLC, non-small cell lung carcinoma; PET, positron emission tomography; PETvol, metabolic tumor volume; SD, standard deviation; SCLC, small-cell lung carcinoma, SUVmax, maximum standardized uptake value; SUVmean, mean standardized uptake value; TLG, total lesion glycolysis; UICC, Union for International Cancer Control. aMicrovessel density data only available from 15 patients (15 NSCLC, thereof 9 adenocarcinoma, 5 squamous cell carcinoma, 1 large cell carcinoma). bWithout the single neuroendocrine tumor.